Quantitative modelling predicts the impact of DNA methylation on RNA polymerase II traffic by Cholewa-Waclaw, Justyna et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative modelling predicts the impact of DNA methylation
on RNA polymerase II traffic
Citation for published version:
Cholewa-Waclaw, J, Shah, R, Webb, S, Chhatbar, K, Ramsahoye, B, Pusch, O, Yu, M, Greulich, P,
Waclaw, B & Bird, A 2019, 'Quantitative modelling predicts the impact of DNA methylation on RNA
polymerase II traffic', Proceedings of the National Academy of Sciences.
https://doi.org/10.1073/pnas.1903549116
Digital Object Identifier (DOI):
10.1073/pnas.1903549116
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Proceedings of the National Academy of Sciences
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Sep. 2019
Submission PDF
Quantitative modelling predicts the impact of DNA
methylation on RNA polymerase II trafﬁc
Justyna Cholewa-Waclaw1, Ruth Shah1, Shaun Webb1, Kashyap Chhatbar1, Bernard Ramsahoye1, Oliver Pusch2, Miao
Yu3, Philip Greulich4, Bartlomiej Waclaw1, Adrian P Bird1
1University of Edinburgh, 2Medical University of Vienna, 3Ludwig Institute for Cancer Research, La Jolla, 4University of Southampton
Submitted to Proceedings of the National Academy of Sciences of the United States of America
Patterns of gene expression are primarily determined by proteins
that locally enhance or repress transcription.Whilemany transcrip-
tion factors target a restricted number of genes, others appear
to modulate transcription levels globally. An example is MeCP2,
an abundant methylated-DNA binding protein that is mutated in
the neurological disorder Rett Syndrome. Despite much research,
the molecular mechanism by which MeCP2 regulates gene expres-
sion is not fully resolved. Here we integrate quantitative, multi-
dimensional experimental analysis and mathematical modelling
to indicate that MeCP2 is a novel type of global transcriptional
regulator whose binding to DNA creates "slow sites" in gene
bodies. We hypothesise that waves of slowed-down RNA poly-
merase II formed behind these sites travel backward and indirectly
affect initiation, reminiscent of defect-induced shock waves in
non-equilibrium physics transport models. This mechanism differs
from conventional gene regulation mechanisms, which often in-
volve direct modulation of transcription initiation. Our ﬁndings
point to a genome-wide function of DNA methylation that may
account for the reversibility of Rett syndrome in mice. Moreover,
our combined theoretical and experimental approach provides a
general method for understanding how global gene expression
patterns are choreographed.
MeCP2 j Gene regulation j Mathematical modelling j DNA methyla-
tion
Introduction
Many eukaryotic chromatin-associated factors modulate tran-
scription by binding to specific sites in gene promoters or en-
hancers (1, 2). Most transcription factors are thought to modu-
late the initiation rate of transcription by altering histone-DNA
interactions (2, 3) or imposing promoter-proximal obstacles (4).
However, transcription can also be affected by processes that
occur in the bodies of genes. In particular, DNA methylation,
which is widespread in gene bodies, appears to affect progression
of RNA polymerase II (RNA Pol II) through densely methylated
exons (5). The mechanism is unclear, but methyl-CpG binding
proteins (6) may be involved. Since most gene bodies contain
methylated CpGs, such proteins may have a global effect on
transcription.
One putative global modulator is methyl-CpG binding pro-
tein 2 (MeCP2) (7, 8), which is highly expressed in neurons.
MECP2 mutations, including loss-of-function or gene duplica-
tion, lead to severe neurological disorders (9, 10). MeCP2 does
not behave as a conventional transcription factor with discrete
targets, as its binding site occurs on average every 100 base
pairs. Evidence from in vitro systems (11, 12) and mouse models
(13, 14) suggests that MeCP2 can mediate DNA methylation-
dependent transcriptional inhibition. Transcriptional changes in
mouse brain when MeCP2 is absent or over-expressed are rela-
tively subtle but widespread (15-17), and the molecular mecha-
nisms underlying these changes are unknown.
Here we set out to resolve the mechanism of MeCP2-
dependent transcriptional regulation. Because MeCP2 binding
sites occur in the vast majority of genes, we reasoned that most
are likely to be influenced to some extent by its presence. To
confront the technical and analytical challenges posed by modest
changes in expression of large numbers of genes, we adopted a
quantitative approach that combined deep, high quality datasets
obtained from a uniform population of Lund Human Mes-
encephalic (LUHMES)-derived human dopaminergic neurons
(18) with computational modelling. We created a spectrum of
LUHMES cell lines expressing distinct levels of MeCP2. Using
transposase-accessible chromatin sequencing (ATAC-seq) and
chromatin immunoprecipitation (ChIP-seq) together with math-
ematical modelling, we detected a robust footprint of MeCP2
binding to mCG and mCA in vivo and determined the amount
of MeCP2 bound to DNA. Quantification of mRNA abundance
by RNA-seq revealed a relationship between changes in tran-
scription and the density of mCG on gene bodies. To explain this
observation, we proposed and tested several distinct mechanistic
models. The only model consistent with our experimental results
is one in whichMeCP2 leads to slowing down of RNApolymerase
II progression through a transcription unit. Importantly, mutant
MeCP2 that is unable to bind the TBL1/TBLR1 subunits of the
NCoR co-repressor complex fails to repress efficiently, suggesting
that repression depends upon this interaction.
Results
Global changes in transcription correlate with MeCP2 expres-
sion level. We created progenitor cell lines capable of differ-
entiation to a uniform population of human neurons (SI Ap-
pendix, Fig. S1A-C) that expressed seven widely different levels
of MeCP2, including knock-out (KO), wild-type (WT) and 11-
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Fig. 1. Gene expression strongly correlateswith gene bodymCGdensity and
MeCP2 abundance. (A) Experimental design (Methods). (B) Mean number
of MeCP2 molecules per nucleus. (C) Log­2 fold change of gene expression
(Log2FC) relative to appropriate controls (ctr – unmodiﬁed controls; SCR
– scrambled shRNA control, OE ctr – overexpression control) for all seven
levels of MeCP2, plotted against gene body mCG density. All Log2FC values
have been shifted so that Log2FC averaged over all genes is zero. Black
line indicates the maximum slope. (D) The maximum slope for gene bodies
varies proportionally to MeCP2 abundance. (E) Ratio between luciferase
expressions from an unmethylated and gene-body methylated constructs,
for three cases: no MeCP2, WT MeCP2, and an MBD mutant R111G that is
unable to bind mCG. Points show individual replicates. In all panels, error
bars represent +/- SEM.
fold over-expression (11x) (Fig. 1A,B and SI Appendix, Fig. S1D
and Table S1). All lines differentiated into neurons with similar
kinetics, expressed neuronal markers (SI Appendix, Fig. S1E),
and had identical global levels of DNA methylation (3.7% of
all cytosines were methylated) (SI Appendix, Fig. S2A). Based
on the known affinity of MeCP2 for methylated CG (mCG), we
expected that the effect of MeCP2 on gene expression would
depend on their mCG content. DNA methylation was therefore
quantified for all genes in WT neurons using whole-genome
bisulfite sequencing (TAB-seq) (SI Appendix, Fig. S2B,C). We
calculated total methylation (total mCG, ) as the number of
methylated CG dinucleotides, mCG density as the number
of mCGs per 100 bp, and mCG mean as the percentage of mCG
in all CG dinucleotides. To determine the effects of MeCP2 on
transcription, we performed RNA-seq on all seven cell lines.
We included all expressed protein-coding genes ( genes)
in our analysis. Most genes responded to MeCP2 but changes
Fig. 2. MeCP2 occupancy on the DNA is proportional to mCG density and
MeCP2 level. (A) MeCP2 ChIP- and ATAC-seq experimental procedures and
their in silico counterparts. and are probabilities of background andMeCP2-
bound reads, respectively. Tn5 insertion sites (scissors) occur in exposed
DNA regions. (B) ChIP-seq enrichment proﬁles centred at mCG dinucleotides
for different cell lines. Black lines represent in silico proﬁles ﬁtted to the
experimental data. (C) MeCP2 ChIP-seq enrichment data in OE 11x/KO (red)
as a function of mCG density. (D) Average depletion proﬁles (logarithm of
the ratio between the number of Tn5 insertions in a given cell line and
KO1, 2-4 biological replicates) in the +/-100 bp regions surrounding mCG
dinucleotides. Black lines represent computer simulations of themodel ﬁtted
to the data. (E) Predicted fraction of mCGs occupied by MeCP2 versus MeCP2
level obtained from depletion proﬁles in (D). Error bars represent +/- SEM.
were small, precluding definition of a subset of affected genes (SI
Appendix, Fig. S3A). To enhance a possible relationship between
expression changes and DNA methylation that otherwise might
be obscured by other regulatory mechanisms and statistical noise,
genes were binned according to methylation density, considering
gene bodies and promoters separately.
The average change in expression versus appropriate con-
trols (Log2FC) showed a strong relationship to mCG density
in gene bodies (Fig. 1C). The effect was the strongest for
=0.8–4.0 mCG per 100bp which includes the vast majority
of genes (SI Appendix, Fig. S3B). The apparent stimulation of
expression at very low mCG densities in OE neurons is discussed
in SI Appendix. Moreover, the maximum slope of the Log2FC
versus in gene bodies (Fig. 1C, black lines) was strikingly
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Fig. 3. MeCP2 does not regulate transcription via condensation of chromatin
or premature termination. (A) A cartoon of the Condensationmodel. Tangles
represent regions of condensed chromatin that are inaccessible to RNA Pol
II. (B) Chromatin accessibility (measured by ATAC-seq) at promoters rapidly
decreases with increasing promoter methylation. In contrast, MeCP2 has a
minor effect on accessibility (curves for OEs 4x and 11x are slightly lower
than for KO). (C) The Condensationmodel disagrees with Log2FC(OE 11x/KO)
obtained from RNA-seq. (D) Schematic representation of the Detachment
model. (E) Log2FC (gene expression) for KO/ctr (purple) versus the total
number of mCGs per gene. Black lines represent predictions of Detachment
model. Error bars represent +/- SEM. (F) As (E) for OE 11x/OE ctr (red).
proportional to MeCP2 levels (Fig. 1D). In contrast, plots of
Log2FC versus in promoter regions showed a slope close
to zero, indicating minimal dependence onpromoter methyla-
tion (SI Appendix, Fig. S3C). No clear dependence on MeCP2
level was observed for Log2FC versus total gene body mCG or
mCG mean (SI Appendix, Fig. S3D,E). These results indicated
that the gene-body mCG density is the strongest predictor of
MeCP2-dependent transcriptional changes. This relationship is
not affected when data are filtered by significance, gene length
or promoter methylation (SI Appendix, Fig. S4A-D). Moreover,
the relationship is maintained even when intronic reads are an-
alyzed suggesting that pre-mRNA is affected in the same way
as processed RNA (SI Appendix, Fig. S4E). To test for a causal
relationship, we transfected cells with two versions (methylated
or unmethylated gene body) of a luciferase reporter gene with
a methylation-free promoter in the presence of wildtype or
the DNA binding mutant MeCP2[R111G] (SI Appendix, Fig.
S5A,B). We observed a two-fold repression of methylated versus
unmethylated luciferase gene body in the presence ofWTMeCP2
compared to either no MeCP2 or mutant MeCP2 (Fig. 1E).
MeCP2 binds predominantly methylated CG genome-wide.
To map the binding of MeCP2 in human neurons, we performed
MeCP2 ChIP-seq for KO, WT, OE 4x and OE 11x, and simul-
taneously developed a computer model that simulates the ChIP-
seq procedure andMeCP2 binding in vivo (Fig. 2A). As expected,
ChIP enrichment was proportional to the level of MeCP2 in each
cell line (SI Appendix, Fig. S6A-C) and showed a strong peak
centred at mCGs in MeCP2-positive lines (Fig. 2B) as well as a
correlation between MeCP2 enrichment and mCG density (Fig.
2C). Conversely, enrichment was absent at non-methylated CGs
(SI Appendix, Fig. S6E).
To derive an independent measure of absolute MeCP2 den-
sity on the DNA and to detect its molecular footprint with high
resolution, we performed ATAC-seq (19) in which transposase
Tn5 cuts exposed DNA to reveal DNA accessibility within chro-
matin (Fig. 2A). In agreement with the ChIP-seq data, ATAC-
seq Tn5 insertion profiles (Fig. 2D) showed a graded depletion
of insertion sites centered around mCG in WT, OE 4x and
OE 11x neurons, whose amplitude was proportional to MeCP2
concentration (Fig. 2E) and therefore represents a “molecular
Fig. 4. Mathematical modelling indicates that MeCP2 slows down transcrip-
tional elongation. (A) Schematic representation of the Dynamical obstacles
model. (B) Transcription rate predicted by the model, plotted as a function
of the initiation rate , for different mean MeCP2 densities in gene bodies.
(C) Space-time plots (kymographs) representing Pol II moving along the
gene. Queues of Pol II induced by MeCP2 can reach TSS (red dot) and
block initiation if both the initiation rate (α) and the density of MeCP2
(ρ) are sufﬁciently high (left panel). (D) Schematic representation of Pol II
(grey) density shock waves forming behind MeCP2 (blue). Black line is the
local density of Pol II. (E) Log2FC (gene expression) versus mCG density in
gene bodies obtained in computer simulations of the Dynamical obstacles
model (black solid lines) ﬁtted to the OE 11x/OE ctr RNA-seq dataset (red)
agrees well with experimental data for OE 4x/OE ctr (orange) and KO/ctr
(purple) datasets. Error bars represent +/- SEM. (F) The maximum slope of
Log2FC (gene expression) versus mCG density in gene bodies, predicted by
the Dynamical obstacles model (black line). Points are experimental slopes
from Fig. 1C.
footprint” of MeCP2 binding in vivo. The size and amplitude of
the footprint agrees well with a computer model of ATAC-seq
and MeCP2 binding (Fig. 2D, black lines) and previous in vitro
data (20, 21), confirming that MeCP2 occupies 11bp of DNA
in living cells. No depletion of insertion sites was observed over
unmethylated CG (SI Appendix, Fig. S6F). The model revealed
that only of mCG sites are actually occupied by MeCP2 in
OE 11x neurons, falling to less than 1% occupancy in WT (Fig.
2E), perhaps due in part to occlusion by nucleosomes. Excellent
agreement between themodels andATAC-seq and ChIP-seq data
allows us to predict MeCP2 occupancy from mCG density and
MeCP2 level in each cell line (Fig. 2E and SIAppendix, Fig. S6D).
MeCP2 does not regulate transcription via condensation of
chromatin or premature termination. To interpret these results
mechanistically, we considered mathematical models based on a
commonly accepted paradigm for gene expression (SI Appendix,
Fig. S7A) (22). In the first class of models named Condensation
models (Fig. 3A), MeCP2 affects the rate of transcription ini-
tiation via changes in chromatin structure. The possibility that
MeCP2 affects the initiation rate by binding to promoters was
rejected because it would imply a stronger correlation between
gene expression and in promoters than in gene bodies, con-
trary to our observations (SI Appendix, Fig. S3C). MeCP2 could
hypothetically affect the fraction of cells with specific genes in
theON state via some long-distancemechanism involving binding
to gene bodies and leading to changes in the degree of chro-
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
Footline Author PNAS Issue Date Volume Issue Number 3
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
Submission PDF
Fig. 5. MeCP2 slows down transcription via a mechanism involving NCoR.
(A)Location of two binding domains in MeCP2 that are relevant for the pro-
posed mechanism: methyl-CpG binding domain (MBD) and NCoR-interaction
domain (NID). The mutation R111G causes MeCP2 to lose the ability to bind
speciﬁcally to mCG. The mutation R306C prevents MeCP2 from binding the
NCoR complex. (B) Level of MeCP2 (Western blot) in two overexpressed
mutant cell lines (R111G and R306C) and the overexpression control cell
line (OE ctr). OE 11x is shown for comparison. Values are averaged over
three biological replicates and normalised by the level of histone H3. (C)
Log2FC (expression) of OE R111G/OE ctr shows almost no dependence on
mCG density in gene bodies (black). Grey line shows the maximum slope. (D)
Log2FC (expression) of OE R306C/OE ctr shows a small negative correlation
with gene body mCG density (brown). Grey line shows the maximum slope.
(E)Maximum slopes for all cell lines including OE R111G (black) andOE R306C
(brown) from (C and D) versus MeCP2 level (Western blot). In all plots error
bars represent +/-SEM.
matin openness near promoters. However, mapping chromatin
accessibility using ATAC-seq showed that while there is a weak
correlation between MeCP2 and accessibility (Fig. 3B), it cannot
account for the observed Log2FC in gene expression (Fig. 3C).
We next considered potential effects of MeCP2 on the elon-
gation phase of transcription. The Detachment Model posits that
MeCP2 causes transcription to prematurely abort (Fig. 3D). Since
the probability of termination increases with each blocking site,
under this model the Log2FC is a function of the total number of
methylated CGs ( ) in the gene: , where
is MeCP2 concentration relative to WT, and the parameter
is proportional to the probability that Pol II aborts transcription
when it encounters MeCP2 or an MeCP2-induced chromatin
modification. The unknown parameter can be obtained by
fitting the model to the Log2FC (KO/WT) data (Fig. 3E). We
found that the model failed to reproduce the Log2FC vs
relationship for theOE 11x cell line (Fig. 3F). Themodel also fails
to correctly predict the observed relationship between Log2FC
and mCG density in gene bodies (SI Appendix, Fig. S7B,C).
Therefore, it is unlikely that MeCP2 affects transcription via
premature termination.
MeCP2 creates “Dynamical obstacles” that impede transcrip-
tional elongation. Finally, we considered a “Congestion model”
whereby Pol II pauses when it encounters MeCP2 itself or an
induced, transient structural modification of chromatin (Fig. 4A).
The parameters are: the fraction of mCGs bound by MeCP2,
MeCP2 turn-over (unbinding) rate , and (specific to each gene)
the length of the gene, the density of methylated CGs,
and the initiation rate . Fig. 4B shows the transcription rate for
OE 11x predicted by the model as a function of , for different
mean MeCP2 densities ( ). The assumed value of
s-1 is compatible with the reported in vivo residence time of
MeCP2 on chromatin (25-40s (23)). Inspired by non-equilibrium
statistical mechanics approaches that have been utilised to model
one-dimensional transport (24, 25), we expect a non-equilibrium
phase transition from a low-density to a maximal-current (con-
gested) phase as the initiation rate or the density of obstacles
increase beyond a critical point. Indeed, all curves in Fig. 4B
have a characteristic shape: a linear relationship for small ,
followed by saturation at high initiation rates. Saturation occurs
due to congestion as polymerases queue upstream of obstacles
(Movies S1,2). However, even in the non-saturated regime of in-
termediate , excluded-volume interactions between polymerases
that have been slowed down by an obstacle cause a density shock
wave that propagates backwards (Fig. 4C). A small increase in
the density of polymerases near the promoter decreases the rate
of Pol II binding to the TSS. Thus, even though MeCP2 does
not directly affect Pol II initiation, it does so indirectly by shock
waves that form behind MeCP2-induced obstacles in gene bodies
(Fig. 4D). To test the model against RNA-seq data, we estimated
average initiation rates for genes with similar mCG densities by
fitting the model to Log2FC data from one of the cell lines (OE
11x/OE ctr; Fig. 4E left and SI Appendix, Fig. S8F).We then used
the model to predict Log2FC for the remaining 6 cell lines. The
model strikingly reproduces the data (Fig. 4E for OE 4x and KO)
as well as the slopes of the Log2FC plots for all seven cell lines
(Fig. 4F). A similar behaviour occurs in amodifiedmodel in which
Pol II slows down (rather than completely stops) on permanent or
long-lasting structural modifications of chromatin (SI Appendix,
Fig. S8A-E,Movie S3). We conclude that both congestion models
are compatible with the experimental data presented in Fig. 1C
andD. Themodels also predict that Log2FC should decrease with
increasing expression (measured as TPMs) in agreement with the
data (SI Appendix, Fig. S8G).
MeCP2 binding to both DNA and NCoR are essential to
slow down RNA Pol II. To address the question of whether
MeCP2 impedes Pol II progression directly by steric interference
or indirectly by altering chromatin structure (e.g., by histone
deacetylation (26)), we overexpressed mutated forms of MeCP2
in the presence of WT MeCP2. The mutants were either unable
to bind methylated DNA (R111G) (27) or unable to recruit the
histone deacetylase complex NCoR (R306C) (14, 28) (Figs. 5A
and SI Appendix, Fig. S9A). As expected, 7-fold overexpression
of MeCP2-R111G caused no mCG-density dependent transcrip-
tional changes (Figs. 5B,C and SI Appendix, Fig. S9B,C). The
R306C mutant, on the other hand, was predicted to repress
transcription if inhibition is directly due to MeCP2 binding to
DNA, but not if inhibition is mediated via the corepressor. In fact,
11-fold overexpression of MeCP2-R306C relative to WTMeCP2
caused only a small perturbation of gene expression, indicating a
significant loss of DNA methylation-dependent repression (Figs.
5B,D and SI Appendix, Fig. S9B,C). The weak slope may rep-
resent minor direct interference of DNA-bound MeCP2-R306C
with transcription. As neither mutant falls on the line defining
the linear relationship between gene repression and MeCP2 con-
centration (Fig. 5E), our findings favour a predominantly indirect
mechanism of repression, whereby corepressor recruitment alters
the chromatin state to impede transcription.
Concluding remarks
In summary, a close alliance betweenmathematicalmodelling
and molecular biology has allowed us to discriminate molecular
mechanisms underlying the relatively subtle global effects of
MeCP2 on global gene expression. The proposed mechanism
relies on MeCP2-NCoR interaction that slows down the pro-
gression of Pol II during transcription elongation. A candidate
mediator of this effect is histone modification, in particular his-
tone deacetylation, as cell transfection assays using methylated
reporters demonstrate that repression depends upon histone
deacetylase activity (11, 12). According to this scenario, MeCP2
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recruitment of the histone deacetylase corepressor NCoR would
restrain transcription, perhaps by causing tighter binding of nucle-
osomes to DNA (26). To explain the dramatic reversibility of Rett
syndrome in animal models (29) we propose that, in the absence
of MeCP2, DNA methylation patterns are unaffected, allowing
the re-expressed wildtype protein to bind within gene bodies and
commence normal modulation of transcriptional elongation. We
suggest that the Congestion model may apply to proteins other
than MeCP2. For example, other chromatin-binding factors that
bind short (and thus abundant) motifs, including other methyl-
binding proteins, may modulate gene expression by a similar
mechanism.
Materials and methods
Cell lines. The procedure for culture and differentiation of the LUHMES cell
line was previously described (18). To create two independentMECP2 knock-
out lines, we used CRISPR-mediated gene disruption (30). To generateMeCP2
knock-downs, several shRNAs against MeCP2 were designed using Sigma-
AldrichMission shRNA online software. Two shRNAs were chosen and cloned
into pLKO.1 vector including scrambled shRNA as a control and lentiviruses
were created (SI Appendix, Table S2). To increase the level of MeCP2 we
created lentiviruses expressingMeCP2 from two alternative promoters in the
pLKO.1 vector: Synapsin and cytomegalovirus (CMV). Calculation of standard
deviation, standard error of mean and t tests for qPCR, Western blots,
methylation and total RNA quantiﬁcation using HPLC were performed using
GraphPad Prism version 7.
Repression assay. CpG-free vector containing Fireﬂy Luciferase with
CpGs was methylated by M.SssI methyltransferase in presence or absence
of SAM. Mouse embryonic ﬁbroblasts were transfected using Lipofectamine
2000 with three plasmids containing: Fireﬂy Luciferase, Renilla Luciferase
and MeCP2. Luciferase activity measurements were performed using Dual
Luciferase assay kit (Promega) according to manufacturer protocol.
Library preparation for Illumina sequencing. All libraries were se-
quenced as 75- or 100-nucleotide long paired-end reads on HiSeq 2000
and HiSeq 2500 Illumina platforms. Methylome of wildtype LUHMES-derived
neurons at day 9 was obtained by TAB-seq according to the published
protocol (31). RNA-seq library was performed according to manufacturer
protocol for ScriptSeq Complete Gold kit (Human/Mouse/Rat). Total RNA
was isolated from all generated cell lines (SI Appendix, Table S1) at day 9
of differentiation using either the RNeasy Mini kit or the AllPrep DNA/RNA
Mini kit (Qiagen). ATAC-seq in four cell lines (KO, WT, OE 4x and OE 11x, SI
Appendix, Table S1) was performed as in (32).
MeCP2 ChIP-seq was performed using LUHMES-derived neurons at day
9 of differentiation with four levels of MeCP2: KO, WT, OE 4x and OE 11x (SI
Appendix, Table S1). Libraries were prepared using the NEBNext Ultra II DNA
library Prep kit (NEB) for both IPs and corresponding inputs.
Data processing of raw reads from Illumina sequencing. All reads
were quality-controlled, trimmed to remove adapters (Trimmomatic) (33),
and duplicated reads, and mapped to the human hg19 reference genome.
Bismark (34) was used to extract cytosine methylation from TAB-seq. All raw
data were deposited in GEO database (accession number GSE125660).
RNA-seq data analysis. We used a subset of protein-coding genes with
sufﬁcient methylation coverage (BS-seq; 80% C detected as methylated,
coverage 20), and gene bodies 1kb or longer. This resulted in 15382 genes
out of the initial 17764 protein-coding genes (86%). In all plots of Log2FC
of differential gene expression we shifted the Log2FC values so that the
average Log2FC in the range of mCG density /100bp was zero for
all samples. This was motivated by a difﬁculty in determining the absolute
levels of expression since we did not quantify total mRNA.
ChIP-seq enrichment proﬁles. We ﬁrst obtain accumulated counts (the
number of reads) that overlap with -th basepair to the right ( ) or
left ( ) from feature ( mCG, mCA,…). We then calculate enrichment
proﬁles as
where and are accumulated counts from ChIP and input (ge-
nomic) DNA sequencing, respectively, and normalizes the counts
proﬁles such that their ﬂanks have values close to one:
We consider a particular C to be methylated if it is methylated in 100% of
the reads, and the coverage is at least 5. We consider a C to be unmethylated
if it does not show up in any of the ChIP-seq reads as methylated.
Computer model of ChIP-seq. We assume that MeCP2 occupies methy-
lated cytosines with probability times the probability of binding to a
particular motif. Binding probabilities for different motifs are based on
known binding afﬁnities (35) and relative binding strengths (15). To create
simulated ChIP fragments, we assume that if a DNA fragment contains at
least one MeCP2 bound to it, it will be present in the simulated ChIP-seq.
Fragments that do not contain anyMeCP2may still be present in the ChIP-seq
data with probability which accounts for “background” reads in ChIP-seq
even in the absence of MeCP2. This is similar to previous models of ChIP-seq
(36); even best ChIP-seq libraries can have a signiﬁcant level of noise ( close
to 1) (37). We also add CG- and length bias, and process simulated reads in
the same way as the experimental ChIP data.
For each ChIP-seq data set we ﬁtted the simulated proﬁle(parametrized
by ) to the experimental proﬁle. Any gives a good ﬁt (SI
Appendix, Fig. S6D), indicating that is the upper bound on mCG
occupancy in 11x OE. We used best-ﬁt parameters to predict proﬁles on
features other than mCG (SI Appendix, Fig. S6E).
ATAC-seq footprints. ATAC-seq was analysed in a similar way to ChIP-
seq, except that we used fragments’ endpoints (Tn5 insertion sites) to
generate accumulated counts . We calculated the insertion proﬁles as
where and are the insertion counts proﬁles for a given cell line
and KO1, respectively, and normalizes the counts proﬁles such that
their ﬂanks have values close to one:
Computer model of ATAC-seq. We use the same binding model as in the
ChIP-seq simulations. We assume that MeCP2 occupies 11bp (20) and that the
protein is centred on anmC.We simulate the action of the Tn5 transposase by
splitting the sequence into fragments in areas free of MeCP2, and we include
Tn5 sequence bias, and CG- and length bias. Themodel has three parameters:
the density of MeCP2 on mCxx, the average density of insertion (cut) sites
, and the GC bias . We process simulated DNA fragments in the same way
as described above for the experimental data. We examined the role of the
parameters on the shape and depth of the simulated footprint of MeCP2 and
concluded that the footprint is not affected as long as the test and control
samples have been processed in a similar way. To extract MeCP2 occupancy
from ATAC-seq data, we ﬁtted the model (free parameters , and a ﬁxed
) to experimental footprints for all four cell lines. The relationship is
linear (Fig. 2E), with the best-ﬁt .
Chromatin accessibility from ATAC-seq. For each gene, we calculated
its mean insertion count and selected regions (“insertion peaks”) in which
. Accessibility was deﬁned as the sum of all insertions in the peaks
divided by the “background” :
Mathematical models of gene expression. The condensation model assumes
that the fraction of cells in which gene is actively transcribed depends
on promoter openness (measured by ATAC-seq) which in turn depends on
the level of MeCP2 and gene methylation : .
The model predicts that of the ratio of gene expression of cell
line X versus cell line Y should yield the same curve (plus a constant) as
the logarithm of the ratio of accessibilities of X versus Y when plotted as a
function of . Data does not support this model (Fig. 3C). The detachment
model poses that the probability that RNA Pol II successfully terminates is
where is the number of “abort sites” on the gene,
proportional to the number of MeCP2 molecules on the gene, and is the
abortion probability. We show that
where is an unknown parameter identical for all cell lines, and
are MeCP2 levels in cell lines X and Y. The model is rejected (Fig. 3F).
We consider two mechanisms by which MeCP2 could affect elongation.
To implement the slow sites model we use the totally asymmetric simple
exclusion process (TASEP) with open boundaries (24). A gene is represented
as a chain of sites. Each site (equivalent to 60bp of the DNA) is either
occupied by a particle (RNA Pol II) or is empty. Particles enter the chain at
site with rate (transcription initiation rate), move along the chain
and exit at site with rate sec-1. Sites can be “fast” or “slow”. Slow
sites represent mCGs affected by the interaction with MeCP2, whereas fast
sites are all other sites (methylated or not). Particles jump with rate
sec-1 (equivalent to Pol II speed 60bp/s) on fast sites and sec-1 on
slow sites. Slow sites are randomly and uniformly distributed with density
where is the probability that an mCG is occupied by MeCP2. To
relate this model to the mRNA-seq differential expression data we calculate
Log2FC as
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where , in which are MeCP2 occupation
probabilities for cell lines X,Y. In the above expression we know all quantities
except the initiation rate which we ﬁt to the OE 11x data.
The dynamical obstacles model is very similar with two exceptions: (i)
Pol II always moves with the same speed (no slow sites) as long as it
is not blocked by other polymerases and obstacles, (ii) obstacles bind and
unbind dynamically from the methylated sites. We assume that unbinding
occurs with rate per obstacle, whereas binding occurs with rate per
unoccupied mCG. Obstacles do not bind if an mCG is already occupied by
an obstacle or a polymerase. We assume that obstacles are not restricted to
accessible mCGs and that their density on actively transcribed genes may be
higher than obtained from ATAC-seq but still proportional to MeCP2 level.
We found that reproduces Log2FC data for all cell lines.
Additional details for Materials and Methods are provided in SI Ap-
pendix.
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